Henrique Tada, executive director of ALANAC, the association gathering Brazilian pharmaceutical companies, provides an historical overview of the rapid and eye-catching growth of the local pharmaceutical industry and documents the new development opportunities envisioned by domestic manufacturers with regards to botanical and biological drugs as well as their competitive advantages in international markets.
Over the past few years, how has the importance of domestic pharmaceutical companies been evolving among the Brazilian healthcare ecosystem?
"Our main competitive advantage on international markets relates to the proven quality of the pharmaceutical products developed and manufactured in Brazil."
